SGLT2i vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin
This cohort study uses target trial emulation to evaluate risk of incident gout and rate of recurrent gout flares in patients with type 2 diabetes initiating sodium-glucose cotransporter-2 inhibitors (SGLT2i) vs sulfonylurea.